---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199382"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:43:21.078623+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Seres Q2 net loss $32.9M; VOWST sales $14.4M (+43% QoQ); announces $175M asset sale to Nestlé

## Summary
- Net loss $32.9M vs net income $46.6M in Q2 2023 (prior year included $125M VOWST milestone from Nestlé).
- VOWST Q2 net sales $14.4M, up 43% sequentially; Seres share of profit/loss was a $6.6M net loss.
- VOWST asset sale to SPN (Nestlé) provides $175M cash less ~$20M settlement; proceeds to retire Oaktree debt.
- SER-155 Phase 1b Cohort 2 placebo-controlled readout on track for September; SER-147 IND readiness H2 2025.
- Cash $71.2M at June 30; with deal proceeds expects runway into Q4 2025; without deal into Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-199382
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524199382/0001193125-24-199382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524199382/d881755d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199382
- JSON: https://secwatch.observer/filing/0001193125-24-199382.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.